equine immunoglobulin anti SARS-CoV-2

Equine immunoglobulin anti SARS-CoV‑2 is a passive immunotherapy product consisting of polyclonal antibodies derived from the plasma of horses that have been hyperimmunized with inactivated or recombinant antigens from the SARS-CoV‑2 virus, including spike protein (S1), receptor binding domain (RBD), nucleocapsid, and other viral proteins. The preparation typically involves enzymatic digestion to produce F(ab')₂ fragments, removing the Fc region to reduce adverse reactions while retaining strong neutralizing activity. These antibodies exhibit high titers and broad neutralization capacity against multiple variants of concern and interest, including Delta and Omicron lineages. The therapy is designed for intravenous administration as a treatment for moderate to severe COVID‑19 cases, especially where monoclonal antibody therapies may be less accessible or effective due to variant escape. Clinical studies indicate good tolerability and potential efficacy in reducing disease severity[[1]][[3]][[5]].

Brand names

CoviFab

Other names

anti-SARS-CoV-2 equine immunoglobulinanti-SARS-CoV2 equine immunoglobulinanti-SARS-CoV 2 equine immunoglobulinanti-SARS-CoV-2 equine F(ab')2 immunoglobulinequine hyperimmune serum against SARS-CoV-2equine polyclonal antibody against SARS-CoV-2